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Background. Factors promoting the emergence of human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT) connection domain mutations and their effect on antiretroviral therapy (ART) are still largely
undetermined. We investigated this matter by analyzing genotypic resistance tests covering 400 amino acid positions
in the RT of HIV-1 subtype B viruses and corresponding treatment histories and laboratory measurements.
Methods. The emergence of connection domain mutations was studied in 334 patients receiving monotherapy
or dual therapy with thymidine analogues at the time of the genotypic resistance test. Response to subsequent
combination ART (cART) was analyzed using Cox regression for 291 patients receiving unboosted protease in-
hibitors. Response was defined by ever reaching an HIV RNA level !50 copies/mL during the first cART.
Results. The connection domain mutations N348I, R356K, R358K, A360V, and A371V were more frequently
observed in ART-exposed than ART-naive patients, of which only N348I and A360V were nonpolymorphic (with
a prevalence of !1.5% in untreated patients). N348I correlated with M184V and predominantly occurred in patients
receiving lamivudine and zidovudine concomitantly. A360V was not associated with specific drug combinations
and was found to emerge later than M184V or thymidine analogue mutations. Nonpolymorphic connection domain
mutations were rarely detected in the absence of established drug resistance mutations in ART-exposed individuals
(prevalence, !1%). None of the 5 connection domain mutations associated with treatment showed a statistically
significant effect on response to cART.
Conclusions. Despite their frequent emergence, connection domain mutations did not show large detrimental
effects on response to cART. Currently, routine implementation of connection domain sequencing seems unnec-
essary for developed health care settings.
All currently approved drugs can lose their efficacy
when human immunodeficiency virus type 1 (HIV-1)
becomes resistant to antiretroviral therapy (ART) [1,
2]. Many mutations that confer resistance to specific
antiretroviral compounds have been characterized [3].
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Because of the mode of action of nucleoside reverse
transcriptase inhibitors (NRTIs) and nonnucleoside re-
verse transcriptase inhibitors (NNRTIs), these amino
acid changes are mostly located in the N-terminal re-
gion of the p66 subunit of the HIV reverse transcriptase
(RT) (amino acid residues 1–321). Additionally, it has
been shown that residues in the connection domain
(322–440) and RNase H region (441–560) of RT may
also confer resistance to antiretroviral drugs, and mul-
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tiple in vitro studies have explored the possible mechanisms of
resistance [4–11]. In contrast, relatively little is known about
the dynamics and factors promoting the emergence of con-
nection domain mutations in vivo. Analyses of genotypic se-
quences from ART-naive and ART-exposed HIV-infected in-
dividuals have identified several amino acid changes in the
connection domain that are significantly associated with any
exposure to ART [9, 12–15], but drug-specific studies are rare.
Through transfection experiments, Brehm et al [8] have in-
vestigated the emergence of connection domain mutations un-
der selective pressure of zidovudine and found that A371V
rapidly followed the established thymidine analogue mutations
(TAMs) K70R and D67N. Yap et al [9] have studied the dy-
namics of the emergence of N348I, one of the few mutations
consistently identified as treatment associated in prevalence
studies. By analyzing genotypic tests from routine clinical care,
they observed that N348I emerged at about the same time as
M184V in the course of treatment but considerably earlier than
TAMs. The selection of N348I was primarily associated with
zidovudine use, and the risk was further enhanced through the
concomitant administration of the NNRTI nevirapine. Hachiya
et al [13] further speculated about a role for didanosine in the
N348I selection, although on the basis of limited observational
data. Recently, we have found evidence for a strong association
between N348I and M184V, reflected by a 5-fold higher rate
of N348I emergence in patients receiving zidovudine and la-
mivudine together, compared with that in patients receiving
zidovudine alone [16].
To date, evidence for an effect of connection domain mu-
tations on the response to ART is very sparse. Yap et al [9]
observed an increase in plasma HIV RNA level after the emer-
gence of N348I. In contrast, Hachiya et al [17] noted no dif-
ference in initial HIV RNA decline on ART in 21 individuals
for whom connection domain mutations (other than N348I)
were present in baseline samples, compared with that in a con-
trol group for whom connection domain mutations were not
present. Brehm et al [18] investigated the role played by con-
nection domain mutations in 60 patients newly initiating efa-
virenz and 2 NRTIs, who later experienced virological rebound
during therapy within the setting of the AIDS Clinical Trials
Group (ACTG) 5142 trial. Their matched comparison includ-
ing baseline and failure samples yielded no connection domain
mutations that were significantly associated with rebound. Pa-
redes et al [19] studied the effect of connection domain mu-
tations on the response to NNRTI-based combination therapy
in 287 patients from EuroSIDA. The only mutation associated
with a higher risk of virological failure was A376S in a subset
of 115 patients receiving nevirapine. In a subanalysis of the
OPTIMA (Options in Management with Antiretrovirals) trial,
Dau et al [20] reported an association between the presence of
at least 1 of a set of 13 connection domain mutations and a
lack of a decrease in HIV RNA level by 1 log10 copies per
milliliter after 24 weeks of therapy.
In the present study, we aimed to investigate the in vivo
dynamics of the emergence of connection domain mutations
in patients who received monotherapy or dual therapy with
NRTIs, including the thymidine analogues zidovudine or sta-
vudine. Moreover, we set out to assess the effect of connec-
tion domain mutations on the response to the first combi-
nation ART (cART) consisting of 2 NRTIs and either an un-
boosted protease inhibitor (PI) or an NNRTI.
METHODS
Viral sequences spanning the full protease and the first 400
amino acids of the RT from 3 different studies were pooled for
this analysis: 351 sequences from the ACTG 320 trial (http://
hivdb.stanford.edu/pages/clinicalStudyData/ACTG320.html)
[21, 22], 1188 sequences from the Swiss HIV Cohort Study
(SHCS) (GenBank accession nos. of sequences used for the
present study: GQ848100–GQ848156) [23, 24], and 11 se-
quences from a lamivudine monotherapy trial (GenBank ac-
cession nos. GU301078–GU301088) [25]. From this data set,
we selected subtype B sequences that were obtained while pa-
tients were receiving ART with thymidine analogue treatment
(with or without lamivudine or didanosine), provided that the
patient had never taken NNRTI or PI drugs at the time of
genotypic testing ( ). Twenty-five patients with exposurenp 334
to both didanosine and lamivudine were excluded. As a sen-
sitivity analysis, we repeated all statistical calculations on a data
set restricted to tests performed while patients were receiving
zidovudine, zidovudine-lamivudine, or zidovudine-didanosine
as the first ART (first-line sample; ). These sensitivitynp 71
analyses generally did not change point estimates but often no
longer returned statistically significant P values. Therefore, we
only report results from the larger sample because of the greater
statistical power.
To study the dynamics of the emergence of connection do-
main mutations, we first screened the RT region for mutations,
which were enriched in patients with exposure to NRTI mono-
therapy or dual therapy. Drug resistance mutations were defined
according to the International AIDS Society–USA (IAS-USA)
list of December 2008 [3]. For the present analysis, we com-
plemented our data with 521 subtype B sequences generated
before any ART exposure. The prevalence of mutations was
then compared between NRTI-experienced and ART-naive pa-
tients by the Fisher exact test. After adjustment for multiple
testing, only mutations with a significantly higher prevalence
among treated compared with therapy-naive patients were con-
sidered for the following analyses. Next, we tested whether any
of the mutations in the set of therapy-associated amino acid
changes were associated with exposure to a specific NRTI drug,
using the Fisher exact test. We further investigated patterns of
622 • CID 2010:51 (1 September) • von Wyl et al
Figure 1. Prevalence of mutations associated with exposure to antiretroviral therapy (ART). Shown is the prevalence of 37 reverse transcriptase
mutations with a statistically significant higher prevalence (after correction for multiple testing) among samples from 334 patients who received
nucleoside reverse transcriptase inhibitor monotherapy or dual therapy, compared with that among 521 samples from ART-naive individuals (see Table
1). The lower and upper ends of bars represent the observed prevalence in untreated and treated human immunodeficiency virus (HIV) infected
individuals, respectively. Black bars indicate International AIDS Society–USA drug resistance mutations (December 2008 list).
covariation between mutations by performing a hierarchical
clustering analysis and by plotting cluster trees. Similarity scores
between pairs of mutations (ie, the probabilities for co-occur-
rence of mutations) for clustering analyses were calculated on
the basis of the Jaccard index, which is the proportion of se-
quences with a co-occurrence of 2 specific mutations, divided
over all sequences with at least 1 of the mutations from that
pair [26]. Robustness of results was tested by repeating the
analysis on resampled data sets (bootstrapping) [27]. Comple-
mentary to the clustering analysis, we used Bayesian networks
to investigate dependencies between established resistance mu-
tations with connection domain mutations [28].
The clinical relevance of connection domain mutations in
patients receiving the first cART consisting of 2 drug classes
was evaluated using 2 separate analyses: the first assessed vi-
rological failure, defined as either nonresponse (1500 HIV RNA
copies/mL at week 24) or a later rebound of viremia to levels
1500 copies/mL, and the second assessed response to treatment,
defined as achieving a viral load !50 copies/mL at least once.
The failure analysis included 331 individuals initiating the first
treatment with no-longer-recommended combination therapy
with 2 NRTIs and an unboosted PI [29], of whom 85 individ-
uals who were not included in the dynamics study because of
concomitant exposure to didanosine and lamivudine or ex-
posure to NNRTIs before genotypic testing. The response anal-
ysis was restricted to a subset of these 331 patients with HIV
RNA quantifications determined using a detection threshold of
50 copies/mL ( ). In addition, we analyzed 40 patientsnp 291
who received the first NNRTI treatment and for whom a ge-
notypic resistance test result obtained before cART initiation
was available. Because the timing of HIV RNA quantification
was strictly controlled within the ACTG 320 study protocol but
not within the SHCS, we performed a discrete time survival
analysis, whereby failure or response to cART was not evaluated
at the exact time of detection but only to a level of predefined
12-week intervals [30]. Follow-up was censored after 48 weeks
of therapy or if a patient changed cART before week 48 without
having experienced an event. Study baseline was set at the time
of cART initiation. Multivariable Cox regression was used to
adjust for baseline differences in the genotypic sensitivity score
of cART (as determined by the Stanford algorithm [31]), HIV
RNA level, and CD4 cell count and to assess the effect of
connection domain mutations on end points.
Statistical analyses were performed using Stata 11 SE (Sta-
taCorp). Bayesian network analysis was conducted using B-
course [32]. The level of significance was set at 5%, and all P
values are 2-sided. The Benjamini-Hochberg correction with a
false-discovery rate of 5% was applied to all P values, to restrict
the proportion of false-positive associations resulting from
multiple testing [33].
RESULTS
Association between connection domain mutations and NRTI
monotherapy or dual therapy. We discovered a total of 37
mutations that were significantly more prevalent in patients
with exposure to ART (Figure 1 and Table 1), of which 11
(black bars in Figure 1) are listed as drug resistance mutations
by the IAS-USA [3]. In addition, a number of treatment-as-
sociated mutations not considered to be primary resistance
Table 1. Associations between Human Immunodeficiency Virus Type 1 Reverse Tran-
scriptase Mutations and Antiretroviral Therapy
Mutation
Treatment
naive
(n p 521)
Treatment
exposed
(n p 334) P a
TA only
(n p 113)
TA 3TC
(n p 20)
TA ddI
(n p 201) P b
T39A 24 (4.6) 41 (12.3) !.001 8 (7.1) 3 (15.0) 30 (14.9) NS
M41L 9 (1.7) 136 (40.7) !.001 32 (28.3) 7 (35.0) 97 (48.3) .002
K43E 2 (0.4) 13 (3.9) !.001 2 (1.8) 0 (0) 11 (5.5) NS
K43Q 1 (0.2) 15 (4.5) !.001 4 (3.5) 1 (5.0) 10 (5.0) NS
K43N 1 (0.2) 9 (2.7) .001 0 (0) 0 (0) 9 (4.5) NS
E44D 2 (0.4) 34 (10.2) !.001 3 (2.7) 2 (10.0) 29 (14.4) .002
D67N 8 (1.5) 110 (32.9) !.001 30 (26.5) 2 (10.0) 78 (38.8) .005
T69N 4 (0.8) 23 (6.9) !.001 9 (8.0) 1 (5.0) 13 (6.5) NS
T69D 2 (0.4) 27 (8.1) !.001 8 (7.1) 0 (0) 19 (9.4) NS
K70R 4 (0.8) 115 (34.4) !.001 40 (35.4) 3 (15.0) 72 (35.8) NS
L74V 2 (0.4) 14 (4.2) !.001 0 (0) 0 (0) 14 (7.0) .004
V75I 0 (0) 5 (1.5) .009 0 (0) 0 (0) 5 (2.5) NS
K104N 5 (1.0) 30 (9.0) !.001 11 (9.7) 0 (0) 19 (9.4) NS
V118I 13 (2.5) 56 (16.8) !.001 7 (6.2) 4 (20.0) 45 (22.4) !.001
Y181C 0 (0) 8 (2.4) .001 0 (0) 0 (0) 8 (4.0) NS
M184V 1 (0.2) 21 (6.3) !.001 2 (1.8) 17 (85.0) 2 (1.0) !.001
E203K 0 (0) 10 (3.0) !.001 0 (0) 2 (10.0) 8 (4.0) NS
E203D 3 (0.6) 12 (3.6) .002 3 (2.7) 1 (5.0) 8 (4.0) NS
H208Y 4 (0.8) 33 (9.9) !.001 7 (6.2) 2 (10.0) 24 (11.9) NS
L210W 4 (0.8) 92 (27.5) !.001 15 (13.3) 3 (15.0) 74 (36.8) !.001
T215S 3 (0.6) 28 (8.4) !.001 11 (9.7) 2 (10.0) 15 (7.5) NS
T215N 2 (0.4) 17 (5.1) !.001 9 (8.0) 1 (5.0) 7 (3.5) NS
T215D 5 (1.0) 15 (4.5) .002 2 (1.8) 0 (0) 13 (6.5) NS
T215I 2 (0.4) 14 (4.2) !.001 2 (1.8) 1 (5.0) 11 (5.5) NS
T215Y 3 (0.6) 173 (51.8) !.001 51 (45.1) 6 (30.0) 116 (57.7) NS
T215F 2 (0.4) 47 (14.1) !.001 10 (8.9) 1 (5.0) 36 (17.9) NS
D218E 0 (0) 15 (4.5) !.001 1 (0.9) 0 (0) 14 (7.0) NS
K219E 0 (0) 5 (1.5) .009 0 (0) 0 (0) 5 (2.5) NS
K219Q 7 (1.3) 71 (21.3) !.001 18 (15.9) 1 (5.0) 52 (25.9) NS
L228R 0 (0) 15 (4.5) !.001 0 (0) 0 (0) 15 (7.5) .004
L228H 2 (0.4) 15 (4.5) !.001 2 (1.8) 1 (5.0) 12 (6.0) NS
R284K 6 (1.1) 17 (5.1) .001 4 (3.5) 1 (5.0) 12 (6.0) NS
E312Q 4 (0.8) 3 (0.9) NS 1 (0.9) 1 (5.0) 1 (0.5) NS
G335C 10 (1.9) 2 (0.6) NS 0 (0) 0 (0) 2 (1.0) NS
G335D 15 (2.9) 2 (0.6) NS 1 (0.9) 1 (5.0) 0 (0) NS
N348I 2 (0.4) 14 (4.2) !.001 4 (3.5) 7 (35.0) 3 (1.5) !.001
R356K 79 (15.2) 76 (22.8) .006 27 (23.9) 5 (25.0) 44 (21.9) NS
R358K 41 (7.9) 50 (15.0) .001 15 (13.3) 3 (15.0) 32 (15.9) NS
A360V 6 (1.1) 29 (8.7) !.001 11 (9.7) 2 (10.0) 16 (8.0) NS
A360I 1 (0.2) 2 (0.6) NS 1 (0.9) 0 (0) 1 (0.5) NS
V365I 19 (3.7) 18 (5.4) NS 5 (4.4) 2 (10.0) 11 (5.5) NS
T369I 1 (0.2) 1 (0.3) NS 1 (0.9) 0 (0) 0 (0) NS
A371V 31 (5.9) 68 (20.4) !.001 20 (17.7) 5 (25.0) 43 (21.4) NS
A376S 48 (9.2) 28 (8.4) NS 9 (8.0) 2 (10.0) 17 (8.5) NS
E399D 72 (13.8) 27 (8.1) NS 8 (7.1) 2 (10.0) 17 (8.5) NS
NOTE. Data are no. (%) of patients, unless otherwise indicated. 3TC, lamivudine; ddI, didanosine; NS,
not statistically significant; TA, thymidine analogue.
a P values are for the difference in prevalence between treatment naive and treatment exposed (Fisher
exact test). Only P values that remained statistically significant after adjustment for multiple testing are
shown.
b P values are for the difference in prevalence across the type of TA treatment (Fisher exact test). Only
P values that remained statistically significant after adjustment for multiple testing are shown.
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Figure 2. Clustering of connection domain and drug resistance mutations. Shown are the results of hierarchical clustering analysis of 37 mutations
significantly associated with exposure to antiretroviral therapy from 334 subtype B sequences. Only bootstrap values 190% (out of 100 replications)
are shown.
mutations by the IAS-USA were observed [27, 34]. A total of
5 mutations located in the C-terminus of the RT were found
to be significantly associated with therapy, of which N348I,
A360V, and A371V have previously been described as possibly
conferring drug resistance. The mutations R356K, R358K, and
A371V were quite common in therapy-naive patients (preva-
lence, 15%) and are most likely polymorphic. As a control, we
examined the prevalence of these 5 and other previously de-
scribed connection domain mutations (E312Q, G335C/D,
A360I, V365I, T369I, A376S, and E399D) in patients exposed
to lamivudine monotherapy. For the 11 patients for whom
baseline and during-treatment genotypic sequences were avail-
able, we did not find amino acid changes in the connection
domain, with the exception of mutations R356K (3/11 [27.3%])
and R358K (2/11 [18.2%]) (data not shown).
Several of the mutations selected in the above analysis also
showed statistically significant heterogeneity across the 3 treat-
ment groups zidovudine, zidovudine-lamivudine, and zido-
vudine-didanosine (Table 1). As expected, the drug-specific
mutations M184V and L74V were almost exclusively observed
among patients with the appropriate exposures (lamivudine
and didanosine, respectively). The TAMs M41L and L210W
were more frequently seen in patients exposed to zidovudine-
didanosine [35]. The only connection domain mutation sig-
nificantly linked to a specific treatment was N348I, which was
more frequently selected in patients receiving zidovudine-la-
mivudine (Table 1 and [16]). The remaining connection do-
main mutations could not be attributed to a specific zidovu-
dine-containing therapy.
Dynamics and covariation of connection domain
mutations. When assessing covariation of mutations (Figure
2), only a few discernible patterns emerged. Aside from the
expected clustering of mutations belonging to the TAM path-
ways [36], the only robust pattern observed was the linkage of
the connection domain mutation N348I with M184V. No fur-
ther patterns became apparent when we repeated the clustering
analysis for each treatment group separately. Next, we explored
dependencies in the appearance of the selected mutations using
Bayesian network analysis (Figure 3). TAM clusters were ob-
served in treatment-experienced patients, as seen with the hi-
erarchical clustering analysis shown in Figure 2. A linked path-
way was observed between mutations M184V and N348I,
restricted to exposure to both lamivudine and zidovudine. The
appearance of the mutation A360V toward the end of pathways
suggested a later emergence relative to the IAS-USA mutations.
On the basis of these observations, we speculated that the emer-
gence of selected mutations follows the hierarchical order
M184V ! N348I ! TAMs ! A360V. Genotypic test results were
assigned to 4 groups on the basis of the latest mutation present
according to the proposed ordering (eg, a genotypic test result
indicating the presence of M184V and TAMs would be attrib-
uted to the TAM group). We then compared the duration of
exposure to thymidine analogues at the time of genotypic test-
ing with respect to the 4 mutation groups and found that
M184V had the shortest duration (median, 252.5 days; inter-
quartile range [IQR], 161–344 days; ), followed by N348Inp 2
(median, 577 days; IQR, 478–894 days; ), TAMs (median,np 5
994 days; IQR, 492–1772.5 days; ), and A360V (me-np 228
dian, 1285 days; IQR, 336–1758 days; ); the differencenp 29
reached marginal statistical significance ( , Jonckheere-Pp .077
Terpstra test for ordered alternatives).
Taken together, the data on the dynamics of mutation emer-
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Figure 3. Bayesian network showing dependencies in the emergence
of resistance mutations. All patients ( ) received zidovudine eithernp 334
alone or in combination with didanosine or lamivudine. A directed arrow
between 2 mutations (eg, M184V and N348I) or between an antiviral
drug and a mutation (eg, lamivudine and M184V) suggests a direct in-
fluence. For example, interpretations for the arrows connecting lamivudine
exposure, M184V, and N348I are that M184V is selected by the antiret-
roviral drug lamivudine and that N348I predominantly occurs when M184V
is already present. Note that the mutation R356K is not shown because
it is independent from all other mutations. Moreover, the arrow from
didanosine exposure to lamivudine exposure is an artefact from the anal-
ysis, because patients were selected such that they could have only
received either lamivudine or didanosine. 3TC, lamivudine; AZT, zidovu-
dine; ddI, didanosine.
gence imply that the appearance of nonpolymorphic connec-
tion domain mutations N348I and A360V does not precede
currently known drug resistance mutations and that these mu-
tations are associated with other known IAS-USA drug resis-
tance mutations. To further test this hypothesis, we screened
the full SHCS drug resistance database of 1188 HIV sequences
covering the first 400 amino acids of the RT for the presence
of connection domain mutations. This analysis showed that
nonpolymorphic connection domain mutations (N348I and
A360V, in particular) were only rarely found in the absence of
other drug resistance mutations (in !1% of genotypic tests for
ART-exposed patients) and at a prevalence similar to that in
ART-naive patients (data not shown; all , Fisher exactP 1 .16
test). This suggests that if no nucleoside analogue resistance
mutations are detected in samples from ART-exposed patients,
an extended search for nonpolymorphic connection domain
mutations would most likely return negative results.
Effect of the presence of connection domain mutations on
the outcome of cART. We proceeded to assess therapy out-
comes of cART for individuals with prior thymidine analogue
exposure and who for the first time started cART with 2 NRTIs
and an unboosted PI ( ) or an NNRTI ( , ofnp 331 np 40
whom 37 received efavirenz). Patients receiving boosted PI were
not considered because of low numbers.
In addition to the connection domain mutations significantly
associated with ART, we included the mutation A376S in the
analysis [19]. As shown in Table 2, the proportion of patients
with a virological response !50 copies/mL to combination ther-
apy with a first-generation unboosted PI was 46% and increased
to 65% in patients receiving an NNRTI. After adjustment for
the genotypic sensitivity score of combination therapy and the
HIV RNA level and CD4 cell count at the start of cART, none
of the tested connection domain mutations reached statistical
significance after correction for multiple testing in this set of
highly ART-exposed individuals. The Cox models with viro-
logical failure as the end point also showed no significant as-
sociations between connection domain mutations and treat-
ment response. Although these negative results could have been
caused by insufficient statistical power, given the observed effect
sizes, a post-hoc simulation showed that larger effects on treat-
ment response (ie, response rates of !18% for the mutations
N348I and A360V, which had the smallest group sizes) could
have been detected with 180% power by a univariable Fisher
exact test.
DISCUSSION
This data set of 334 subtype B sequences provided a unique
opportunity to study the dynamics of drug resistance emer-
gence, because all patients included in this analysis were re-
ceiving nonsuppressive NRTI treatments until the time of ge-
notypic testing. We observed 5 mutations located in the HIV
RT connection domain that were significantly more frequent
in NRTI-exposed than NRTI-naive patients. Of these muta-
tions, only N348I and A360V were nonpolymorphic. The anal-
ysis of covariation of mutations confirmed a previous finding
that N348I often co-occurred with M184V and was predom-
inantly selected during therapy containing thymidine analogues
and lamivudine. Moreover, our Bayesian network analysis sug-
gested a late occurrence of A360V relative to IAS-USA muta-
tions. Despite their relatively frequent emergence, connection
domain mutations did not seem to have a major effect on the
response to cART in this population with high exposure to
zidovudine monotherapy or dual therapy. Because these mu-
tations mainly increase resistance against thymidine analogues
and leave PIs and lamivudine unaffected, this was to be ex-
pected for the patients starting treatment with unboosted PIs.
Because of limited sample size, no firm conclusions could be
reached with regard to the effect of connection domain mu-
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Table 2. Response to First Combination Antiretroviral Therapy (cART)
Parameter
Virological failurea Virological responsea
Proportion (%) HR (95% CI) Proportion (%) HR (95% CI)
cART with unboosted PI
Overall
Drug naive at baselineb 16/90 (17.8) 53/77 (68.8)
Drug exposed at baseline 105/331 (31.7) 135/291 (46.4)c
Drug exposed, by mutation
N348I 4/15 (26.7) 0.79 (0.26–2.47) 7/11 (63.6) 1.78 (0.72–4.39)
R356K 29/79 (36.7) 1.07 (0.70–1.64) 30/72 (41.7) 0.98 (0.65–1.49)
R358K 22/47 (46.8) 1.47 (0.88–2.46) 15/38 (39.5) 0.84 (0.49–1.44)
A360V 10/28 (35.7) 1.50 (0.72–3.13) 14/27 (51.9) 1.02 (0.59–1.76)
A371V 23/69 (33.3) 1.08 (0.68–1.72) 25/60 (41.7) 0.84 (0.54–1.32)
A376S 7/23 (30.4) 1.04 (0.53–2.03) 9/19 (47.4) 1.27 (0.75–2.16)
M184V 11/31 (35.5) 0.76 (0.34–1.70) 5/13 (38.5) 0.76 (0.21–2.72)
cART with NNRTI
Overall
Drug naive at baselined 4/133 (3.0) 116/133 (87.2)
Drug exposed at baseline 8/40 (20.0) 26/40 (65.0)
Drug exposed, by mutation
N348I 1/4 (25.0) 1.20 (0.02–66.72) 2/4 (50.0) 0.46 (0.07–3.23)
R356K 3/5 (60.0) 4.31 (0.51–36.68) 2/5 (40.0) 1.56 (0.22–10.91)
R358K 2/7 (28.6) 0.84 (0.12–6.05) 3/7 (42.9) 0.62 (0.17–2.18)
A360V 0/3 (0) NC 3/3 (100) NC
A371V 3/11 (27.3) 0.71 (0.18–2.73) 6/11 (54.6) 1.86 (0.85–4.05)
A376S 2/6 (33.3) 0.94 (0.12–7.25) 3/6 (50.0) 0.81 (0.31–2.18)
M184V 6/27 (22.2) 2.36 (0.25–22.21) 17/27 (63.0) 1.45 (0.48–4.34)
Pooled analysis
Overall
Drug naive at baseline 20/223 (9.0) 169/210 (80.5)
Drug exposed at baseline 113/371 (30.5) 161/331 (48.6)
Drug exposed, by mutation
N348I 5/19 (26.3) 0.95 (0.30–2.95) 9/15 (60.0) 1.23 (0.56–2.70)
R356K 32/84 (38.1) 1.16 (0.76–1.78) 32/77 (41.6) 0.95 (0.64–1.42)
R358K 24/54 (44.4) 1.38 (0.83–2.28) 18/45 (40.0) 0.80 (0.47–1.35)
A360V 10/31 (32.3) 1.42 (0.69–2.92) 17/30 (56.7) 1.22 (0.75–1.98)
A371V 26/80 (32.5) 1.10 (0.72–1.69) 31/71 (43.7) 0.87 (0.58–1.30)
A376S 9/29 (31.0) 1.10 (0.60–2.00) 12/25 (48.0) 1.21 (0.74–1.98)
M184V 17/58 (29.3) 0.89 (0.44–1.78) 22/40 (55.0) 1.30 (0.65–2.59)
NOTE. CI, confidence interval; HR, hazard ratio; NC, not computable; NNRTI, nonnucleoside reverse transcriptase
inhibitor; PI, protease inhibitor.
a Models are adjusted for baseline CD4 cell count, baseline HIV RNA level, and genotypic sensitivity score of ART.
b Connection domain mutations present at cART initiation were R356K ( ), R358K ( ), A360V ( ), A371Vnp 17 np 7 np 2
( ), and A376S ( ), but no association with therapy failure or response was observed in adjusted Cox regressionnp 3 np 5
models (data not shown).
c Only includes individuals for whom all HIV RNA quantifications were performed with a lower threshold of detection
of 50 copies/mL.
d Connection domain mutations present at cART initiation were R356K ( ), R358K ( ), A360V ( ),np 19 np 10 np 1
A371V ( ), and A376S ( ), but no association with therapy failure or response was observed in adjusted Coxnp 6 np 14
regression models (data not shown).
tations on combination therapy with NNRTIs. However, pa-
tients receiving efavirenz or nevirapine exhibited somewhat
higher response rates than did patients receiving unboosted PIs,
despite the presence of connection domain mutations (Table
2). It is worth noting that the majority of the NNRTI-treated
patients received efavirenz. Considering that both N348I and
A376S mutations have been associated with nevirapine resis-
tance, a larger data set is necessary to determine the effect of
these mutations on virological failure in nevirapine-experienced
patients.
What are the implications of these data for clinical practice
and HIV drug resistance testing? Many standard genotypic re-
sistance assays do not cover RT regions beyond amino acid
residue 240, and hence the connection domain or RNase H are
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not included. The issue of whether to include the RT C-ter-
minus genetic region in genotypic sequencing for routine clin-
ical care is debated, especially in light of the expected additional
cost [37, 38]. The clinical and virological effect of these mu-
tations are not well understood in vivo. However, they point
to an at-most subtle effect of N348I, A371V, and A360V on
virologic response to treatment [9, 17–20]. Moreover, the con-
nection domain mutations studied here were rarely observed
in the absence of other IAS-USA mutations in patients exposed
to nucleoside analogue inhibitors. Therefore, the danger of mis-
interpreting genotypic test results as being fully sensitive to all
drugs despite the presence of connection domain mutations is
diminishingly small. Thus, we believe that a pragmatic ap-
proach is required with regard to the sequencing of the con-
nection domain region. As our data clearly demonstrate, the
risk of the emergence of certain connection domain mutations
(such as N348I, A360V, or A371V) is fairly high after prolonged
exposure to virologically failing treatment containing zidovu-
dine (or stavudine). Because certain mutations (such as N348I
and A376S) also affect susceptibility to nevirapine [9], the in-
clusion of connection domain mutations in resistance testing
may be beneficial if a salvage regimen including NNRTIs is
initiated. This reasoning may be of special relevance for Africa,
where generic fixed-dose combinations of stavudine, lamivu-
dine, and nevirapine are commonly used, which may lead to
an increased prevalence—and possibly also transmission—of
connection domain mutations [39]. Thus, although routine
implementation of connection domain and RNase H sequenc-
ing in developed health care settings currently seems unnec-
essary, further research is warranted to study the effect of these
mutations in more specific resource-limited settings.
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